fuzuloparib

Overview

Fuzuloparib (SHR-3162) is an oral PARP1/2 (PARP1) inhibitor under clinical investigation. In the context of NPC, PARP inhibitors including fuzuloparib are being explored in combination with immune checkpoint inhibitors to exploit potential DNA repair deficiencies driven by EBV-associated genomic instability.

Evidence in the corpus

• Cited as a PARP inhibitor (alongside niraparib and olaparib) being tested in combination with ICI in NPC to exploit DNA repair deficiencies PMID:24952746.

Resistance mechanisms

Cancer types (linked)

• NPC

Sources

This page was processed by entity-page-writer on 2026-05-11.